Acadia Pharmaceuticals (ACAD) Change in Receivables (2013 - 2026)

Acadia Pharmaceuticals' Change in Receivables history runs 14 years deep, the most recent figure standing at -$13.7 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 781.89% year-over-year to -$13.7 million; the TTM figure through Mar 2026 stood at $7.0 million (up 15.03% YoY), while the FY2025 annual figure was $22.7 million, up 4713.14% from the prior year.
• Change in Receivables was -$13.7 million for Q1 2026 at Acadia Pharmaceuticals, down from $5.6 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $15.9 million in Q2 2023 to a low of -$13.7 million in Q1 2026.
• Historically, Change in Receivables has averaged $2.6 million across 5 years, with a median of $3.7 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Change in Receivables soared 9443.11% in 2023, then slumped 781.89% in 2026.
• A 5-year view of Change in Receivables shows it stood at -$1.6 million in 2022, then soared by 442.42% to $5.5 million in 2023, then sank by 239.05% to -$7.6 million in 2024, then surged by 173.79% to $5.6 million in 2025, then sank by 345.05% to -$13.7 million in 2026.
• The last three Change in Receivables figures came in at -$13.7 million (Q1 2026), $5.6 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.